Novartis Forecasts 5% Yearly Sales Growth
Healthcare suppliers should note rising peak-sales targets for several established Novartis drugs.
Updated on Nov. 19, 2026 in Healthcare

Swiss drugmaker Novartis forecasts average net sales growth of 5% per year from 2026 to 2031, excluding exchange-rate effects, and raised peak sales estimates for several of its drugs. The company is a major pharmaceutical player, and the outlook signals where healthcare revenue is expected to concentrate over the medium term.
Why it matters
The forecast reflects confidence that existing drugs will keep gaining sales alongside new launches, a pattern that shapes pricing, supply, and partnership decisions across the healthcare sector. Upward revisions to specific products also show where drugmakers expect demand to grow fastest.
Novartis projects 5% average annual net sales growth through 2031, excluding exchange-rate effects. Peak sales forecasts rose to $8 billion each for Kesimpta and Rhapsido, while nine on-market products could each reach $3 billion to $10 billion in annual sales.
The players
Novartis
Swiss pharmaceutical company with a large portfolio of branded prescription drugs, whose revenue depends on sustaining sales of established products while launching new ones.
The details
Novartis expects growth to come from two sources: rising sales of drugs already on the market and new products coming to market. The company raised its peak sales forecasts for Kesimpta, Scemblix, and Leqvio, the first two from $6 billion and $4 billion respectively, which are revisions to prior estimates rather than new launches. The company says its core operating margin is on track to recover to above 40% by 2029.
Timeline
2026 to 2031: projected period of 5% average annual net sales growth.
2029: expected year for core operating margin to recover above 40%.
Market Landscape
The revisions show a major drugmaker raising its ceiling for products already on the market rather than relying only on pipeline launches. That approach sets a benchmark for how established pharmaceutical companies position their long-term sales outlook against competitors.
Operators in healthcare supply, distribution, and services should watch for demand shifts tied to the growth of specific drugs. Finance and procurement teams may find it useful to track how drugmaker revenue plans translate into contracting and pricing terms.
The takeaway
Medium-term revenue plans from large drugmakers increasingly rest on growing established products. Operators should track how such forecasts affect supplier and contracting conditions in the coming quarters.
Further reading
For broader context on how drugmakers plan revenue and pricing, explore our Healthcare coverage.


